vTv Therapeutics Inc - Ordinary Shares - Class A
VTVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$80.43M
Close$
$10.56
65.6% downside
Current Fair Value
65.6% downsideOvervalued by 65.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $80.43 Million |
|---|---|
| Enterprise Value | $-17,658,983.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.2 |
| Beta | 0.25 |
| Outstanding Shares | 8,423,632 |
Return
| Return on Equity | 2.50% |
|---|---|
| Return on Assets | 2.28% |
| Return on Invested Capital | 8.31% |
Valuation & Multiples
| P/E Ratio | 1536.5 |
|---|---|
| PEG | -267.7 |
| Price to Sales | 7.68 |
| Price to Book Ratio | 3.07 |
| Enterprise Value to Revenue | -0.48 |
| Enterprise Value to EBIT | -2.31 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$20.00 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.97
Average shareholder expectationRevenue Estimate
$333,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 17.65% |
|---|---|
| Total Invested | $14,232▼ 99.98% |
| Investors Holding | 3▼ 32.00% |
ESG Score
No data
About vTv Therapeutics Inc
25 employees
CEO: Stephen Holcombe vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and infla...